Physician
Newport Pediatrics, P.C.
Newport Pediatrics, P.C. was paid $11.71M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 32% of everything it billed.
33Billing provider infoNEWPORT PEDIATRICS, P.C.
NEWPORT, TN 37821
NEWPORT, TN 37821
33aNPI1467678706assigned 04/17/2007
33bProvider typePediatrics Physician
28Total paid$11.71M
24GClaims465,170
24DCodes billed84
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Tennessee
Rank by total paid#9 of 333
Median peer was paid$139K
This provider vs. median84×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,690 | $1.14M | |
| 2019 | 52,561 | $1.45M | |
| 2020 | 54,682 | $1.42M | |
| 2021 | 74,110 | $1.89M | |
| 2022 | 91,871 | $2.26M | |
| 2023 | 72,875 | $1.93M | |
| 2024incomplete | 71,381 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 80,857 | 69,586 | $3.72M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 16,873 | 14,815 | $1.19M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.0% | 23,244 | 19,919 | $817K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 6.1% | 25,686 | 19,764 | $716K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.9% | 9,132 | 8,162 | $695K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.8% | 8,772 | 7,492 | $676K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.7% | 6,775 | 6,197 | $556K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.1% | 14,538 | 13,366 | $479K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.7% | 9,399 | 8,619 | $434K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.5% | 5,658 | 4,743 | $406K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.2% | 4,296 | 3,524 | $372K |
| 96160 | 2.9% | 31,380 | 22,566 | $345K |
72 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 22,296 | $182K |
| 92551 | 1.4% | 20,142 | $160K | |
| 99173 | 1.1% | 19,690 | $124K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,792 | $84K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,292 | $76K |
| 99401 | <1% | 3,190 | $75K | |
| 98966 | <1% | 1,198 | $69K | |
| 96127 | <1% | 14,416 | $66K | |
| 98967 | <1% | 853 | $54K | |
| 96161 | <1% | 3,086 | $47K | |
| 99605 | <1% | 755 | $45K | |
| 36416 | <1% | 21,228 | $42K | |
| 99050 | <1% | 1,620 | $26K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,984 | $24K |
| 83655 | <1% | 2,147 | $24K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,900 | $23K |
| 90677 | <1% | 470 | $22K | |
| 3008F | <1% | 24,661 | $21K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,133 | $20K |
| D1206 | Topical application of fluoride varnish | <1% | 895 | $16K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 98 | $11K |
| D0190 | <1% | 893 | $9K | |
| 80061 | Lipid panel | <1% | 651 | $8K |
| 87807 | <1% | 699 | $7K | |
| 94760 | <1% | 4,786 | $6K | |
| 81003 | <1% | 3,018 | $6K | |
| 90651 | <1% | 602 | $5K | |
| 99177 | <1% | 750 | $5K | |
| 0001A | <1% | 167 | $5K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 72 | $5K |
| 0002A | <1% | 140 | $4K | |
| 90461 | <1% | 9,399 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 227 | $4K |
| 82962 | <1% | 966 | $3K | |
| 90670 | <1% | 3,498 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,233 | $3K |
| 99051 | <1% | 4,031 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 127 | $2K |
| 90473 | <1% | 170 | $1K | |
| 90619 | <1% | 96 | $1K | |
| 99381 | <1% | 18 | $1K | |
| 98968 | <1% | 14 | $1K | |
| 90680 | <1% | 1,701 | $667.34 | |
| 90710 | <1% | 138 | $600.00 | |
| 90686 | <1% | 4,160 | $597.94 | |
| 90688 | <1% | 1,236 | $510.55 | |
| 90734 | <1% | 199 | $501.73 | |
| 90698 | <1% | 2,463 | $500.00 | |
| 90621 | <1% | 13 | $468.00 | |
| 0071A | <1% | 13 | $429.28 | |
| 81025 | <1% | 66 | $338.62 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 297 | $325.76 |
| 90633 | <1% | 679 | $251.32 | |
| 94664 | <1% | 13 | $215.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 132 | $166.57 |
| 90661 | <1% | 199 | $151.73 | |
| 90715 | <1% | 89 | $96.31 | |
| 90785 | <1% | 32 | $88.23 | |
| 90744 | <1% | 313 | $84.00 | |
| 90672 | <1% | 225 | $82.76 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 218 | $75.90 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 232 | $26.32 |
| 99000 | <1% | 34,666 | $12.16 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 485 | $9.09 |
| 90674 | 0% | 999 | $0.00 | |
| 90697 | 0% | 295 | $0.00 | |
| 90716 | 0% | 144 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| 90687 | 0% | 374 | $0.00 | |
| 91300 | 0% | 612 | $0.00 | |
| 90707 | 0% | 104 | $0.00 | |
| 90685 | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPUCKETT, SAMUEL (PRESIDENT)